Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growth.

Guan, Lulu; Yang, Yalan; Lu, Yao; Chen, Yu; Luo, Xi; Xin, Dao; Meng, Xiangrui; Shan, Zhengzheng; Jiang, Guozhong; Wang, Feng

Guan, Lulu; Yang, Yalan; Lu, Yao; Chen, Yu; Luo, Xi; Xin, Dao; Meng, Xiangrui; Shan, Zhengzheng; Jiang, Guozhong; Wang, Feng.

Afiliación

Guan L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yang Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lu Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chen Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Luo X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xin D; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Meng X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shan Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiang G; Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wang F; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Front Pharmacol ; 14: 1141420, 2023.

Article en En | MEDLINE | ID: mdl-37168998

Palabras clave

esophageal squamous cell carcinoma; mutant p53; p53; phenethyl isothiocyanate; reactivation

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google